Oseltamivir and Zanamivir are two agents of neuraminidase inhibitors currently available for treatment and prophylaxis 
against influenza type A and type B. They operate in blocking the activity of viral neuraminidase enzyme that is needed to enable new viral particles from being released out infected cells. The following article will describe you about the safety of these neuraminidase inhibitors, oseltamivir and zanamivir.
What you will find in this article are sections discuss about the cause of seasonal influenza, the use of oseltamivir and zanamivir for the treatment of uncomplicated influenza as FDA approval, safety profile of oseltamivir and zanamivir (prophylaxis in adults, treatment in adults and children) including report table of safety outcomes for oral oseltamivir and zanamivir used for treatment and prophylaxis.
In the final section there is an expert opinion outlines that these neuraminidase inhibitors agents have reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life threatening influenza. Read more about The Safety of Oseltamivir and Zanamivir for the Treatment and Prevention of Influenza in this neuraminidase inhibitor article (source: epublications.bond.edu.au)
